Over a 1-year period, 11 isolates (including 5 from blood cultures) of the recently described CDC group 3 and group 5 coryneform bacteria were derived from clinical specimens and compared with reference strains. Biochemical characteristics indicated a very close relationship between CDC group 3 and group 5 coryneform bacteria. The ability of CDC group 3 and the inability of CDC group 5 coryneform bacteria to ferment xylose were the only reactions that were different for the two taxa. Chemotaxonomic features of the two groups included the presence of meso-diaminopimelic acid, a lack of mycolic acids, and the presence of predominantly branched cellular fatty acids, a combination found among gram-positive rods only in Brevibacterium spp., Brachybacteriumfaecium, and Dermabacter hominis. 16S rRNA gene sequence analysis revealed that CDC group 3 and group 5 coryneform bacteria are members of the genus Dermabacter, which to date has been isolated exclusively from human skin.
In recent years, gram-positive coryneform rods (GPCR) have attracted the attention of clinical microbiologists, mainly because of an increased recognition in clinical material but also because of taxonomic interests (9, 22) . The number of defined species and taxa has increased accordingly. In 1992, the Special Bacteriology Reference Laboratory at the Centers for Disease Control and Prevention (CDC), Atlanta, Ga., proposed the new coryneform groups 3 to 7 (16) . Up to now, 18 strains of CDC group 3 and 12 strains of CDC group 5 coryneform bacteria, isolated mainly from blood, have been described (16) . We report here the recovery of 11 additional strains of CDC group 3 and group 5 coryneform bacteria from clinical specimens over a 1-year period and present their clinical, phenotypic, and genotypic characteristics. On the basis of comparative 16S rRNA gene sequence analysis, we demonstrate CDC group 3 and group 5 coryneform bacteria to be members of the recently described genus Dermabacter, containing Dermabacter hominis as the only species. To our knowledge, this report for the first time presents data on the clinical relevance of strains belonging to the genus Dermabacter.
MATERIALS AND METHODS Strains, media, and growth conditions. Clinical samples were cultured aerobically at 37°C with 5% CO2 on Columbia agar with 5% sheep blood (SBA), the same medium containing colistin and nalidixic acid, Columbia chocolate agar, and MacConkey agar without CO2 (all media were purchased from Becton Dickinson Microbiology Systems, Cockeysville, Md., unless specified otherwise). For (26) . Gas-liquid chromatography. Volatile and nonvolatile fatty acids from fermentation of glucose by organisms grown in brain heart infusion broth supplemented with 1% glucose were determined by gas-liquid chromatography (15) on a Sigma 300 chromatograph (Perkin-Elmer, Norwalk, Conn.). For analysis of cellular fatty acid (CFA) patterns, we used the Microbial Identification System (Microbial ID, Inc., Newark, Del.) (MIDI). Cultures were grown for 48 h at 37°C with 5% CO2 on Trypticase soy agar without any additives (TSA) or supplemented with 5% sheep blood (TSBA) (31) .
Analysis of cell wall constituents. meso-Diaminopimelic acid and mycolic acids in whole-cell hydrolysates were detected by the methods described by Schaal (28) .
DNA analysis. Chromosomal DNA was isolated and purified by hydroxyapatite chromatography (6) , and the moles percent G+C content was determined by thermal denaturation (24) .
For rRNA sequence determination, total genomic DNA was isolated by a standard miniprep method (2) . A large fragment of the 16S rRNA gene was amplified by PCR using universal primers pA (nucleotides 8 to 28, Escherichia coli numbering [5] ) and pH* (nucleotides 1542 to 1522) (4) . Direct sequencing of the amplified product was performed by using primers for conserved regions of the rRNA and a Sequenase version 2.0 sequencing kit (United States Biochemical Corp., Cleveland, Ohio) as described previously (18) .
Nucleotide sequence accession number. The nucleotide sequence of the 16S rRNA gene of strain 8 has been deposited with GenBank (EMBL) under accession number X76773.
RESULTS
Clinical data are given in Table 1 . Seven of the 15 strains were isolated from blood cultures. None of our five bloodderived isolates came from a line-drawn specimen. In only 3 of 11 samples, direct Gram strains had been performed but did not show GPCR. In addition to the GPCR, in 4 of 11 cases coagulase-negative staphylococci and in 1 case each E. coli or mixed anaerobic flora were isolated. Strains 13 and 14 were recovered from the same patient at a 2-week interval. Immunosuppression was noted only in 2 of the 10 patients. Eight of 11 strains were from patients hospitalized in seven different medical and surgical wards at the Zurich University Hospital, and three strains came from three other hospitals.
All 15 strains were able to grow under strictly anaerobic conditions. After 24-h incubation at 37°C on SBA, colony sizes ranged from 0.5 to 1.5 mm. Colonies were whitish grey with entire edges. Gram stains revealed relatively small, "coccoid" rods, with no forming of endospores. As evident from Table 2 , biochemical features of CDC group 3 and group 5 coryneform bacteria were very similar (for the remainder of this article, the two groups of bacteria are referred to as group 3 and group 5). The only major phenotypic difference between group 3 and group 5 strains was the inability of group 5 strains to ferment xylose. The type strain of D. hominis was found to have the same biochemical profile as group 5 strains. Minor differences of group 3 and group 5 isolates were noted for lysine decarboxylase, ot-galactosidase, and ,-galactosidase. However, even the activities of the other enzymes, as measured with the API ZYM system, were very similar for group 3 and group 5 strains.
The API CORYNE system identified all 15 isolates as CDC group A coryneform bacteria, with good to very good scores (Table 3) .
Antimicrobial susceptibility testing revealed similar patterns for group 3 and group 5 strains ( resistant to gentamicin, netilmicin, and tobramycin but remained susceptible to amikacin. These five strains were also found to be resistant to clindamycin and rifampin.
Acetic acid and lactic acid were detected as major end products of glucose metabolism.
Group 3 and group 5 strains could not be separated by their CFA patterns. 12-Methyl-tetradecanoic acid (Caii5:0) and 14-methyl-hexadecanoic acid (Cail7:0) were shown to be the major CFAs. In both group 3 and group 5, we also detected relatively large amounts of C9:ocycio omega8c CFA (1 to 7%) with the MIDI system when cells were grown on TSBA. However, this fatty acid could not be detected when strains were grown on TSA (Table 5) .
Cell walls of group 3 and group 5 contained meso-diaminopimelic acid, but mycolic acids were not present.
The G+C contents of both group 3 (n = 2) and group 5 (n = 2) strains were found to be 60 to 62 mol%. Figure 1 depicts the primary 16S rRNA structure of strain 8. Partial sequencing of approximately 600 bases of the 16S rRNA (including variable regions Vl to V3) of strain 3 revealed an almost identical sequence (data not shown).
DISCUSSION
Over a 1-year period, we isolated in our clinical laboratory 11 strains of group 3 and group 5 bacteria. These GPCR were further characterized by biochemical, chemotaxonomic, and molecular methods. A source for these isolates could not be found, but nosocomial transmission seemed most unlikely. However, group 3 and group 5 strains were, in 4 of 11 cases, associated with coagulase-negative staphylococci, suggesting human skin or mucous membranes as a reservoir. For only one patient, a concurrent culture of group 5 bacteria was obtained.
The key reaction to differentiate group 3 and group 5 strains was the fermentation of xylose. None of the other biochemical tests applied proved to be discriminative. In order to place GPCR in their correct taxonomic position, a combination of chemotaxonomic investigations is necessary (12) . The combination of meso-diaminopimelic acid and mainly branched CFAs in GPCR is found only in Brevibactenium spp., Brachybacterium faecium, and D. hominis (7, 8, 19, 20) (Table 6 ). However, assignment of group 3 and group 5 strains to the nonfermentative genus Brevibacterium (20) can be excluded since group 3 and group 5 are fermentative. B. faecium has a significantly higher G+C content (68 to 72 mol%) (7) than group 3 and group 5 strains. Furthermore, B. faecium has so far never been isolated from humans but only from poultry deep litter. The biochemical and chemotaxonomic features of group 3 and group 5 strains, however, are in accordance with the original description of D. hominis (19) . While Jones and Collins (19) described the activities of ot-galactosidase and 13-glucosidase as negative in D. hominis, we detected weak or medium activity, respectively. This discrepancy might be due to the use of different inocula or due to difficulties in reading the API ZYM system, as reported elsewhere (13) . Jones and Collins (19) described ornithine decarboxylase as absent in D. hominis, whereas we observed strong activity of this enzyme in all 15 strains tested by two independent test systems. Additionally, we found lysine decarboxylase in nearly all group 3 and group 5 strains, an enzyme usually not seen in GPCR (lla). The CDC Special Bacteriology Reference Laboratory described the presence of lysine and ornithine decarboxylases initially only in group 5 strains (16) but subsequently also found group 3 strains positive for both lysine and ornithine (16a). Furthermore, Jones (3, 30, 31) . However, this CFA could not be detected when group 3 and group 5 strains were grown on TSA, suggesting that the CFA data for TSBA did not accurately reflect the biosynthetic potential of these strains.
Due to their absence from the API CORYNE data base (1), group 3 and group 5 strains cannot be identified at present with this system. However, group 3 and group 5 strains can easily be distinguished from CDC group A coryneform bacteria (Table  3) , which are motile and produce a yellow pigment (17) . Moreover, cell walls of CDC group A coryneform bacteria do not contain meso-diaminopimelic acid (lla).
Aminoglycoside resistance is usually not encountered in GPCR except in Corynebacterium jeikeium and Corynebacterium urealyticum (10), whereas it is widespread in gramnegative rods (29) . However, our patients' history did not reveal any prior topical or systemical chemotherapy with aminoglycosides, nor did we observe any increase in aminoglycoside resistance in bacteria originating from hospitals where the specimens came from. At present, it remains unclear whether aminoglycoside resistance was acquired or is intrinsic to the strains examined.
To establish the relatedness of group 3 and group 5 strains with the genus Dermabacter, we sequenced the entire 16S rRNA gene of strain 8 and the most characteristic part of the 16S rRNA gene of strain 3. On the basis of a comparison of 31 CGRRCGCTGG CGGCGTGCTT RRCRCRTGCR RGTCGRRCGR TGRRNCTGTG CTTGCRCRGT GGRTTRGTGG CGRRCGGGTG AGTRACRCGT GRGTRACCTG CCCTCCACTT TGGGATRACT CCGRGRARTC GGGGCTRATR CTGGRTRTGR CTRTGGCCCG CRTGGGTTGT GGTGGRRRGT TTTTCGGTGG GGGRTGGGCT CGCGGCCTRT CRGTTTGTTG GTGRGGTAGT GGCTCRCCRR GGCGRTGRCG GGTRGCCGGC CTGRGFIGGGC GRCCGGCCRC RCTGGGRCTG RGACRCGGCC CRGACTCCTR CGGGAGNCRG CRGTGGGGRR TATTGCRCRR TGGGCGRRRG CCTGATGCRG CGRCGCCGCG TGGGGGRTGR CGGCCTTCGG GTTGTRARCC TCTTTCAGCR RGGRRGRAGC GARRGTGRCG GTRCTTGCRG RRGRRGCGCC GGCTRRCTAC GTGCCRGCAG CCGCGGTRRT RCGTRGGGCG CRRGCGTTGT CCRGARTTAT TGGGCGTARR GGGCTTGTRG GTGGCTTGTC GCGTCTNCCG TGRRRRCCCR GGGCTTRRCT CTGGGCGTGC GGTGGGTACG GGCRGGCTRG AGTGCGGTAG GGGRGRCTGG RATTCCTGGT GTRGCGGTGR RRTGCGCRGR TATCRGGAGG RACRCCGRTG GCGRRGGCRG GTCTCTGGGC CGTTRCTGRC ACTGAGRRGC GRARGCRtGG GGRGCGRRCA GGRTTRGATR CCCTGGTRGT CCRTGCCGTR ARCGTTGGGC RCTRGGTGTG GGGRGCRTTC CRCGTTTTCC GCGCCGTRGC TRRCGCRTTR RGTGCCCCGC CTGGGGRGTR CGGCCGCRRG GCTRRRRCTC RRRGGRATTG RCGGGGGCCC GCRCRRGCGG CGGRGCATGC GGRTTRRTTC GRTGCRRCGC GRRGRRCCTT RCCRRGGCTT GRCRTGCRCT GGRTCGCTGC RGRGRTGTGG TTTTCTTTGG RCTGGTGCRC RGGTGGTGCR TGGTTGTCGT CRGCTCGTGT CGTGRGRTGT TGGGTTRRGT CCCGCRRCGR GCGCRRCCCT CGTTCCRTGT TGCCRGCRCT TCGGGTGGGG RCTCRTGGGR GACTGCCGGG GTCRRCTCGG RGGARGGTGG GGRCGRCGTC RMRTCATCAT GCCCCTTATG TCTTGGGCTT CACGCGTGCT RCRATGGTCG GTRCRRTGGG TTGCGRTRCT GTGRGGTGGA GCTARTCCCR ARRAGCCGGT CTCRGTTCGG ATTGGGGTCT GCRRCTCGRC CCTRTGRRGT CGGRGTCGCT RGTRATCGCR GRTCRGCRRT GCTGCGGTGA RTRCGTTCCC GGGCCTTGTR CRCRCCGCCC GTCRRGTCRC GRRRGTCGGT RRCRCCCGRR GCCGRTGGCC CRAGCTTTAT GCNGGGRGTC GTCGRAGGTG GGRTCGGTGR NTGGGRCTRR GTCGTRRCRR GGTRGCCGTR CCGGRRGG 
